Results 181 to 190 of about 34,133,693 (246)

Glucagon-like peptide-1 receptor agonists for heart failure with reduced ejection fraction: Is it the next step? [PDF]

ESC Heart Fail
Biegus J.
europepmc   +1 more source

Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early‐Phase Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The management of the disease of obesity has been transformed by incretin‐based therapies; however, additional and alternative therapeutic strategies are needed to address its biological complexity. This narrative review examines the physiology of amylin and the emerging role of amylin‐based therapies in obesity management.
Abdulhameed Alhazmi, Carel W. le Roux
wiley   +1 more source

Institutional survey of gastric ultrasound usage in patients receiving glucagon-like peptide-1 receptor agonists. [PDF]

Anaesthesia
Michell E, Lange A, Ben-Menachem E.
europepmc   +1 more source

Efficacy and Safety of SGLT2 Inhibitors in Patients With Genetic Lipodystrophy: A Real‐Life Experience From a National Reference Network

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim Lipodystrophy syndromes are rare diseases with metabolic and cardiovascular consequences. This study explores the metabolic and renal effects of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in patients with genetic lipodystrophy. Patients and Methods Patients with familial partial lipodystrophy (n = 57) or congenital generalised ...
Léna Robert, Ines Belalem, Corinne Vigouroux, Hippolyte Dupuis, Marie Christine Vantyghem, Mathilde Simonson, Estelle Nobecourt, Héléna Mosbah, Sophie Beliard, Stéphanie Jellimann, Sonja Janmaat, Camille Vatier, Sophie Lamothe   +12 more
wiley   +1 more source

Glucagon-like Peptide-1 Receptor Agonists and Colorectal Cancer Risk. [PDF]

AACE Endocrinol Diabetes
Winkelman JW, Levine MJ.
europepmc   +1 more source

Amylin: A Multi‐Functional Pancreatic Hormone—A Review

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Amylin is a pancreatic beta‐cell hormone that sits at a systems hub connecting key aspects of energy metabolism. Amylin physiologically controls satiation, slows gastric emptying and limits postprandial glucagon release, while its actions also link homeostatic eating controls with reward driven behaviours via defined central nervous system ...
Christelle Le Foll, Thomas A. Lutz
wiley   +1 more source

WITHDRAWN: Can glucagon like peptide-1 receptor agonists be beneficial for brain health?

Ballabio G, Mason A, Paz V, Dale C, Sofat R, Garfield V.   +5 more
europepmc   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists and Fragility Fracture Risk in Type 2 Diabetes.

JAMA Netw Open
Hamad CD, Wiener J, Golzar A, Kaur H, Henein C, Kittredge AP, Su G, Kaelber DC, Chan L, Yeaman MR, Adams JS, Bernthal NM, Sheppard WL.   +12 more
europepmc   +1 more source

Glucagon-like peptide-1 receptor agonists and pancreatic outcomes in chronic pancreatitis: a real-world cohort study. [PDF]

BMC Gastroenterol
Dhali A, Maity R, Khan F, Biswas J, Faisal AR.   +4 more
europepmc   +1 more source

Quality of Diabetes Care Among Older Adults in Germany—Results of the Study on Health of Older People 2022/2023 Compared With Previous National Health Surveys

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The study aims (1) to evaluate the quality of diabetes care considering guideline‐recommended medical therapies, cardiometabolic factors, and self‐management of health behaviours among older adults with diabetes in Germany, and (2) to examine time trends.
Yong Du, Giselle Sarganas, Beate Gaertner, Maike Buchmann, Judith Fuchs, Hannelore Neuhauser, Christin Heidemann   +6 more
wiley   +1 more source